Monia Garofolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3601488/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	5.5	231
2	HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2301-2310.	4.3	130
3	Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the <scp>RIACE</scp> Italian multicentre study. Journal of Internal Medicine, 2013, 274, 176-191.	2.7	111
4	Chronic kidney disease in type 2 diabetes: Lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 815-822.	1.1	51
5	Sex differences in food choices, adherence to dietary recommendations and plasma lipid profile in type 2 diabetes – The TOSCA.IT study. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 879-885.	1.1	43
6	Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. Cardiovascular Diabetology, 2019, 18, 159.	2.7	43
7	Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. Diabetologia, 2017, 60, 1102-1113.	2.9	38
8	Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. European Journal of Nutrition, 2018, 57, 679-688.	1.8	38
9	Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 361-373.	1.1	37
10	A Fermented Whole Grain Prevents Lipopolysaccharides-Induced Dysfunction in Human Endothelial Progenitor Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-13.	1.9	29
11	Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovascular Diabetology, 2014, 13, 59.	2.7	24
12	Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies. Diabetes Research and Clinical Practice, 2021, 180, 109066.	1.1	24
13	On the non-linear association between serum uric acid levels and all-cause mortality rate in patients with type 2 diabetes mellitus. Atherosclerosis, 2017, 260, 20-26.	0.4	22
14	Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. Journal of Diabetes and Its Complications, 2018, 32, 550-557.	1.2	14
15	Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE): An Inexpensive and Parsimonious Prediction Model. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4900-4908.	1.8	14
16	The Synergic Association of hs-CRP and Serum Amyloid P Component in Predicting All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care, 2020, 43, 1025-1032.	4.3	14
17	Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care, 2020, 43, e139-e141.	4.3	13
18	Insulin discovery: A pivotal point in medical history. Metabolism: Clinical and Experimental, 2022, 127, 154941.	1.5	11

Monia Garofolo

#	Article	IF	CITATIONS
19	The rs12917707 polymorphism at theUMODlocus and glomerular filtration rate in individuals with type 2 diabetes: evidence of heterogeneity across two different European populations. Nephrology Dialysis Transplantation, 2016, 32, gfw262.	0.4	10
20	Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 99-114.	1.1	10
21	Pharmacogenetics of oral antidiabetes drugs: evidence for diverse signals at the IRS1 locus. Pharmacogenomics Journal, 2018, 18, 431-435.	0.9	9
22	Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus. Cardiovascular Diabetology, 2018, 17, 78.	2.7	5
23	<i>SIRT1</i> rs7896005 polymorphism affects major vascular outcomes, not all ause mortality, in Caucasians with type 2 diabetes: A 13â€year observational study. Diabetes/Metabolism Research and Reviews, 2022, 38, e3523.	1.7	3
24	Contribution of rare variants in monogenic diabetes-genes to early-onset type 2 diabetes. Diabetes and Metabolism, 2022, 48, 101353.	1.4	3
25	Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]. Diabetologia, 2017, 60, 2123-2125.	2.9	2
26	Response to Comment on Garofolo et al. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. Diabetes Care 2020;43:e139–e141. Diabetes Care, 2021, 44, e81-e81.	4.3	1
27	All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease. Acta Diabetologica, 2021, 58, 1425-1428.	1.2	0
28	LA MALATTIA RENALE CRONICA NON-ALBUMINURICA NEL DIABETE MELLITO TIPO 1. Il Diabete, 2019, 31, .	0.0	0